<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943655</url>
  </required_header>
  <id_info>
    <org_study_id>HVB</org_study_id>
    <nct_id>NCT02943655</nct_id>
  </id_info>
  <brief_title>Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause</brief_title>
  <official_title>Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow,
      frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual
      abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml
      or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the amount of menstrual blood loss</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Improve Quality of Life</condition>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>combined oral contraceptives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral second generation pills one tablet daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medroxyprogesterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-steroidal anti-inflammatory</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 500 mg mefenamic acid three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined contraceptive pills (microcept)</intervention_name>
    <description>oral combined contraceptive once daily</description>
    <arm_group_label>combined oral contraceptives</arm_group_label>
    <other_name>microcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate (progest)</intervention_name>
    <description>oral 5 mg medroxyprogesterone acetate daily</description>
    <arm_group_label>medroxyprogesterone acetate</arm_group_label>
    <other_name>progest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mefenamic acid (ponstan forte)</intervention_name>
    <description>oral 500 mg mefenamic acid three times per day</description>
    <arm_group_label>non-steroidal anti-inflammatory</arm_group_label>
    <other_name>ponstan forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Regular menstrual cycles with BMI (19-29 kg/m2). Heavy and/or prolonged menstrual bleeding
        involving at least last three consecutive menstrual cycles.

        Exclusion Criteria:

          1. Postmenopausal bleeding (over one year since the last menstrual period).

          2. Irregular menses or intermenstrual bleeding.

          3. Organic causes of heavy menstrual bleeding suspected or confirmed by experienced
             abdominal and transvaginal ultrasound after thorough general and gynecological
             examination.

          4. Iatrogenic (treatment-related) causes of heavy menstrual bleeding (e.g.
             non-progestogen-releasing intrauterine contraceptive device, oral contraceptives,
             other hormonal drug use or anticoagulant agent).

          5. Iron deficiency anemia.

          6. History of chronic diseases known to interfere with menstrual bleeding or prevent the
             use of any of the listed drugs e.g previous or current thromboembolic disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Abbas</name>
      <address>
        <city>Assiut</city>
        <state>Cairo</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed abbas</last_name>
      <email>bmr90@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>June 30, 2018</last_update_submitted>
  <last_update_submitted_qc>June 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefenamic Acid</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

